Research programme: CAR-T cell therapies - AdAlta/Carina Biotech
Latest Information Update: 15 Sep 2021
At a glance
- Originator AdAlta; Carina Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer